Oligonucleotide Synthesis Market to Surpass US$ 6,080.8 Million by 2027 - Coherent Market Insights

Global Oligonucleotide Synthesis Market, by Equipment & Services (Equipment/Synthesizer, Reagents, and Services (Oligo Synthesis, Modification, and Purification)), by Technology (Column-based, and Microarray-based), by Nucleic Acid (DNA and RNA), by Application (Drug Discovery and Therapeutics), by End User (Academic Research Institutes, Diagnostic Laboratories, and Pharmaceutical-Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,874.1 Million in 2020 and is expected to exhibit a CAGR of 11.3% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key companies are focusing on launching new services such as oligonucleotide synthesis, which is expected to drive growth of the global oligonucleotide synthesis market during the forecast period. For instance, in March 2017, Eurofins Genomics launched a DNA synthesis service based on the company's next-generation synthesis platform in the U.S. The service is designed to provide to supply small quantities of high-quality oligonucleotides for molecular biology and synthetic biology.

Global Oligonucleotide Synthesis Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus pandemic has affected each and every market globally. There has been increasing demand for effective treatment against COVID-19. Presently, pharmaceutical companies and healthcare providers are focused on discovering more efficient use of oligonucleotides and its application to prevent the spread of COVID-19. For instance, in 2020, Innovative Genomic Institute stated that they are working on aerosolized locked nucleic acid modified antisense oligonucleotide that can be inhaled or nebulized for the treatment of COVID-19 infection. Such innovations are generating an interest amongst healthcare providers and driving them to fight against COVID-19 pandemic. Thus, COVID-19 has affected the global oligonucleotide synthesis market in a positive way.

Browse 47 Market Data Tables and 35 Figures spread through 167 Pages and in-depth TOC on “Oligonucleotide Synthesis Market”- Global Forecast to 2027, by Equipment & Services (Equipment/Synthesizer, Reagents, and Services (Oligo Synthesis, Modification, and Purification)), by Technology (Column-based and Microarray-based), by Nucleic Acid (DNA and RNA), by Application (Drug Discovery and Therapeutics), by End User (Academic Research Institutes, Diagnostic Laboratories, and Pharmaceutical - Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global oligonucleotide synthesis market, click the link below:

https://www.coherentmarketinsights.com/market-insight/oligonucleotide-synthesis-market-4257

Market players are focusing on developing antisense oligonucleotides for the treatment of various diseases such as Duchenne Muscular Dystrophy (DMD), which is expected to boost the market growth during the forecast period. For instance, in December 2019, Sarepta Therapeutics, Inc. received approval from the U.S. Food and Drug Administration for VYONDYS 53 (golodirsen), an antisense oligonucleotide from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping.

Key Takeaways of the Global Oligonucleotide Synthesis Market:

• The global oligonucleotide synthesis market is expected to exhibit a CAGR of 11.3% during the forecast period, owing to expansion of manufacturing facilities by market players. For instance, in 2018, Corden Pharma GmbH (Germany) expanded its new overseas commercial oligonucleotide active pharmaceutical ingredient manufacturing facility at CordenPharma Colorado in the U.S., which will help to grow its network in Europe and the U.S.
• Among equipment & services, equipment/synthesizer segment held a dominant position in the global oligonucleotide synthesis market in 2019, owing to product launches by market players. For instance, in April 2020 Biolytic Lab Performance Inc., a manufacturer of oligo synthesizers and related lab accessories, introduced its new oligo synthesizer, Dr. Oligo 768XLc, for throughput nucleic acid synthesis.
• Key players operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc., TriLink BioTechnologies, Inc, BioAutomation Corporation, Twist Bioscience, Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, Synbio Technologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, Kaneka Eurogentec S.A., and LGC, Biosearch Technologies